Compare ASTI & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | GRDX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9M | 39.3M |
| IPO Year | 2014 | N/A |
| Metric | ASTI | GRDX |
|---|---|---|
| Price | $7.97 | $5.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 155.1K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,398,149.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.25 | N/A |
| 52 Week Low | $1.40 | $1.87 |
| 52 Week High | $9.87 | $6.93 |
| Indicator | ASTI | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 55.12 |
| Support Level | $2.99 | $2.16 |
| Resistance Level | $9.37 | $6.93 |
| Average True Range (ATR) | 1.79 | 0.65 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 59.03 | 34.17 |
Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.